Please use this identifier to cite or link to this item:
Title: Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Withdrawal Is Associated with Higher Mortality in Hospitalized Patients with COVID-19.
Issue Date: 15-Jun-2021
Citation: J Clin Med.2021;(10)12:
Abstract: Our main aim was to describe the effect on the severity of ACEI (angiotensin-converting enzyme inhibitor) and ARB (angiotensin II receptor blocker) during COVID-19 hospitalization. A retrospective, observational, multicenter study evaluating hospitalized patients with COVID-19 treated with ACEI/ARB. The primary endpoint was the incidence of the composite outcome of prognosis (IMV (invasive mechanical ventilation), NIMV (non-invasive mechanical ventilation), ICU admission (intensive care unit), and/or all-cause mortality). We evaluated both outcomes in patients whose treatment with ACEI/ARB was continued or withdrawn. Between February and June 2020, 11,205 patients were included, mean age 67 years (SD = 16.3) and 43.1% female; 2162 patients received ACEI/ARB treatment. ACEI/ARB treatment showed lower all-cause mortality (p
PMID: 34204014
Rights: openAccess
ISSN: 2077-0383
Appears in Collections:Hospitales > H. U. Infanta Cristina > Artículos

Files in This Item:
File SizeFormat 
PMC8232748.pdf3.97 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons